Literature DB >> 19608667

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

Thomas Clozel, Aline Renneville, Marion Venot, Claude Gardin, Charikleia Kelaidi, Geneviève Leroux, Virginie Eclache, Claude Preudhomme, Pierre Fenaux, Lionel Adès.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19608667      PMCID： PMC2754969          DOI： 10.3324/haematol.2009.010702

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

Authors:  Robert E Gallagher; Beow Y Yeap; Wanli Bi; Kenneth J Livak; Nike Beaubier; Sreenivas Rao; Clara D Bloomfield; Frederick R Appelbaum; Martin S Tallman; James L Slack; Cheryl L Willman
Journal:  Blood       Date:  2002-12-05       Impact factor: 22.113

2.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse.

Authors:  Jesper Stentoft; Peter Hokland; Mette Ostergaard; Henrik Hasle; Charlotte Guldborg Nyvold
Journal:  Leuk Res       Date:  2005-10-21       Impact factor: 3.156

4.  Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.

Authors:  K Tobal; J Newton; M Macheta; J Chang; G Morgenstern; P A Evans; G Morgan; G S Lucas; J A Liu Yin
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

5.  Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

Authors:  H Leroy; S de Botton; N Grardel-Duflos; S Darre; X Leleu; C Roumier; F Morschhauser; J-L Lai; F Bauters; P Fenaux; C Preudhomme
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

Review 6.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

Authors:  Jacques Delaunay; Norbert Vey; Thierry Leblanc; Pierre Fenaux; Françoise Rigal-Huguet; Francis Witz; Thierry Lamy; Anne Auvrignon; Didier Blaise; Arnaud Pigneux; Francine Mugneret; Christian Bastard; Nicole Dastugue; Jacqueline Van den Akker; Denis Fière; Josy Reiffers; Sylvie Castaigne; Guy Leverger; Jean-Luc Harousseau; Herve Dombret
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

7.  New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

Authors:  Susanne Schnittger; Martin Weisser; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

Review 8.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

Authors:  D Diverio; V Rossi; G Avvisati; S De Santis; A Pistilli; F Pane; G Saglio; G Martinelli; M C Petti; A Santoro; P G Pelicci; F Mandelli; A Biondi; F Lo Coco
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

10.  When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

Authors:  Bruno Cassinat; Stéphane de Botton; Charikleia Kelaidi; Lionel Ades; Fabien Zassadowski; Isabelle Guillemot; Marie-Helene Schlageter; Emmanuel Raffoux; Jean-Luc Harousseau; Olivier Legrand; Martine Escoffre-Barbe; Oumedaly Reman; Martine Gardembas; Chantal Himberlin; Jean Yves Cahn; Denis Guyotat; Didier Bouscary; Anne Parry; Philippe Rousselot; Andre Baruchel; Hervé Dombret; Sylvie Chevret; Pierre Fenaux; Christine Chomienne
Journal:  Leuk Res       Date:  2009-01-23       Impact factor: 3.156
  10 in total
  4 in total

1.  Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Authors:  W Zeijlemaker; A Kelder; Y J M Oussoren-Brockhoff; W J Scholten; A N Snel; D Veldhuizen; J Cloos; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

Review 2.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

3.  Ferroptosis-related gene signature predicts the clinical outcome in pediatric acute myeloid leukemia patients and refines the 2017 ELN classification system.

Authors:  Yu Tao; Li Wei; Hua You
Journal:  Front Mol Biosci       Date:  2022-08-11

4.  Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.

Authors:  Biao Wang; Jihong Zhang; Xiaoying Hua; Haiqian Li; Zhilin Wang; Bin Yang
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.